Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery

作者：Zihang Pan, Qiyang Yao, Weijing Kong, Weijing Kong, Xiaojing Ma, Liangliang Tian, Yun Zhao, Shuntian Zhu, Sheng Chen, Mengze Sun, Jiao Liu, Simin Jiang, Jianxun Ma, Qijia Liu, Xiaohong Peng, Xiaoxia Li, Zixuan Hong, Yi Hong, Xue Wang, Xue Wang, Jiarui Liu, Jingjing Zhang, Wei Zhang, Bingbing Sun, Sara Pahlavan, Yuyong Liu, Weimin Shen, Yuyong Liu, Wenjian Jiang, Zhengwei Xie, Wei Kong, Weijia Kong, Xi Wang, Xi Wang, Kai Wang · 发表于：Cell stem cell · 年份：2024 · DOI：10.1016/j.stem.2024.10.015 · 被引用次数：45 · 研究领域：Lymphatic System and Diseases、Angiogenesis and VEGF in Cancer、Extracellular vesicles in disease

Venous malformations (VMs) represent prevalent vascular anomalies typically attributed to non-inherited somatic mutations within venous endothelial cells (VECs). The lack of robust disease models for VMs impedes drug discovery. Here, we devise a robust protocol for the generation of human induced VECs (iVECs) through manipulation of cell-cycle dynamics via the retinoic signaling pathway. We introduce an L914F mutation into the TIE2 gene locus of induced pluripotent stem cells (iPSCs) and show that the mutated iVECs form dilated blood vessels after transplantation into mice, thereby recapitulating the phenotypic characteristics observed in VMs. Moreover, utilizing a deep neural network and a high-throughput digital RNA with perturbation of genes sequencing (DRUG-seq) approach, we perform drug screening and demonstrate that bosutinib effectively rescues the disease phenotype in vitro and in vivo. In summary, by leveraging genome editing and stem cell technology, we generate VM models that enable the development of additional therapeutics.